MOG and myeloid sarcoma: While the ability to diagnose MOGAD has increased in recent years, distinguishing MOGAD from MS remains a challenge, as there are different live cell-based assays for detecting MOG-specific antibodies in serum (and to some extent in CSF) that appear to offer much higher specificity compared with commercial assays that use fixed cells expressing full-length MOG (10).